U.S. uranium enters a policy-driven upcycle as supply risks, energy demand, and digital infrastructure converge to lift prices and revalue domestic miners.
Vistagen’s late-stage CNS pipeline, led by fasedienol™, shows clinical progress and strategic growth despite liquidity pressures and non-material revenue.
Mosaic’s 2026 outlook centers on tightening phosphate markets, resilient potash demand, and margin sensitivity to sulfur costs, key drivers for MOS this year.